Expert views on screening for tuberculosis infection in patients commencing treatment with a biologic agent

Objective: Many biologic agents cause some degree of immunosuppression, which can increase the risk of reactivation of tuberculosis infection (TBI). This risk is variable between individual biologics. We aimed to assess current (and recommended) clinical practice of TBI screening and treatment among...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Jornal brasileiro de pneumologia Ročník 50; číslo 4; s. e20240082
Hlavní autoři:	Sultana1,2, Adiba, Battista Migliori3, Giovanni, D’Ambrosio,4, Lia, García-García5, José-María, Rossato Silva6, Denise, Adrian Rendon5, Luis, R Codecasa7, Luigi, Blanc8, Francois-Xavier, Tiberi9, Simon, W M Ong10,11,12, Catherine, Heffernan13, Courtney, Sotgiu14, Giovanni, Centis3, Rosella, Caroline Dobler1,2, Claudia, Network, The Global Tuberculosis
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Brazil Sociedade Brasileira de Pneumologia e Tisiologia 2024
Témata:	Biological products Biological Products - adverse effects Biological Products - therapeutic use Humans Immunosuppression therapy Latent tuberculosis Latent Tuberculosis - diagnosis Latent Tuberculosis - drug therapy Life Sciences Mass screening Mass Screening - methods Original Recurrence RESPIRATORY SYSTEM Risk Factors Surveys and Questionnaires Tuberculosis Latent tuberculosis Recurrence Latent tuberculosis Biological products Immunosuppression therapy Recurrence Mass screening Biological products Immunosuppression therapy Mass screening
ISSN:	1806-3756, 1806-3713, 1806-3756
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!